2iul: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Human angiotensin-converting enzyme is an important drug target for which, little structural information has been available until recent years. The, slow progress in obtaining a crystal structure was due to the problem of, surface glycosylation, a difficulty that has thus far been overcome by the, use of a glucosidase-1 inhibitor in the tissue culture medium. However, the prohibitive cost of these inhibitors and incomplete glucosidase, inhibition makes alternative routes to minimizing the N-glycan, heterogeneity desirable. Here, glycosylation in the testis isoform (tACE), has been reduced by Asn-Gln point mutations at N-glycosylation sites, and, the crystal structures of mutants having two and four intact sites have, been solved to 2.0 A and 2.8 A, respectively. Both mutants show close, structural identity with the wild-type. A hinge mechanism is proposed for, substrate entry into the active cleft, based on homology to human ACE2 at, the levels of sequence and flexibility. This is supported by normal-mode, analysis that reveals intrinsic flexibility about the active site of tACE., Subdomain II, containing bound chloride and zinc ions, is found to have, greater stability than subdomain I in the structures of three ACE, homologues. Crystallizable glycosylation mutants open up new possibilities, for cocrystallization studies to aid the design of novel ACE inhibitors.
Human angiotensin-converting enzyme is an important drug target for which little structural information has been available until recent years. The slow progress in obtaining a crystal structure was due to the problem of surface glycosylation, a difficulty that has thus far been overcome by the use of a glucosidase-1 inhibitor in the tissue culture medium. However, the prohibitive cost of these inhibitors and incomplete glucosidase inhibition makes alternative routes to minimizing the N-glycan heterogeneity desirable. Here, glycosylation in the testis isoform (tACE) has been reduced by Asn-Gln point mutations at N-glycosylation sites, and the crystal structures of mutants having two and four intact sites have been solved to 2.0 A and 2.8 A, respectively. Both mutants show close structural identity with the wild-type. A hinge mechanism is proposed for substrate entry into the active cleft, based on homology to human ACE2 at the levels of sequence and flexibility. This is supported by normal-mode analysis that reveals intrinsic flexibility about the active site of tACE. Subdomain II, containing bound chloride and zinc ions, is found to have greater stability than subdomain I in the structures of three ACE homologues. Crystallizable glycosylation mutants open up new possibilities for cocrystallization studies to aid the design of novel ACE inhibitors.


==Disease==
==Disease==
Line 16: Line 16:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Acharya, K.R.]]
[[Category: Acharya, K R.]]
[[Category: Corradi, H.R.]]
[[Category: Corradi, H R.]]
[[Category: Natesh, R.]]
[[Category: Natesh, R.]]
[[Category: Sewell, B.T.]]
[[Category: Sewell, B T.]]
[[Category: Sturrock, E.D.]]
[[Category: Sturrock, E D.]]
[[Category: Watermeyer, J.M.]]
[[Category: Watermeyer, J M.]]
[[Category: ACT]]
[[Category: ACT]]
[[Category: CL]]
[[Category: CL]]
Line 45: Line 45:
[[Category: zinc]]
[[Category: zinc]]


''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Feb 3 10:38:23 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 17:56:09 2008''